Document Type : Original Research Article
Authors
1 Assistant Professor of Radiotherapy, Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Assistant Professor of Surgery, Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract
Introduction: Breast cancer is known as the most common cancer in women and various aspects of dealing with this disease have been studied by researchers for many years. One of these areas is tumor markers and its effect on determining the prognosis of patients and determining the most appropriate treatment method. Therefore, we decided to conduct a study to evaluate tumor markers of breast cancer in women candidates for mastectomy.
Methods: The clinical records of 100 patients with breast cancer were evaluated for information such as information about pathological examinations of the sample (markers: ER, PR, HER2, P53, CEA) and recurrence of symptoms during a two-year period. Data were analyzed using SPSS ver17 statistical software, descriptive statistics and logistic regression test.
Results: 24% had recurrence among which P53 and CEA markers had the highest frequency and in the absence of recurrence group ER and CEA markers had the highest frequency.
Conclusion: According to the results of this study, it seems that paying attention to tumor levels of markers such as P53 and CEA can be helpful in identifying people who will have recurrence and attention to it can greatly determine the fate of the disease.
Keywords
Main Subjects
OPEN ACCESS
©2023 The author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/
PUBLISHER NOTE
Sami Publishing Company remains neutral concerning jurisdictional claims in published maps and institutional affiliations.
CURRENT PUBLISHER
Sami Publishing Company
- M. Seely, T. Alhassan, Curr. Oncol., 2018, 25, S115–S124 [crossref], [Google Scholar], [Publisher]
- Jia, Y. Chen, Q. Wang, U. Jayasinghe, X. Luo, Q. Wei, J. Wang, H. Xiong, C. Chen, B. Xu, W. Hu, L. Wang, W. Zhao, J. Zhou, Oncotarget, 2017, 8, 41717–41733 [crossref], [Google Scholar], [Publisher]
- Li, T. Zhang, M. Zheng, Y. Liu, Z. Chen, J. Hematol. Oncol., 2017, 10, 175 [crossref], [Google Scholar], [Publisher]
- P. Hessvik, A. Llorente, Cell. Mol. Life Sci., 2018, 75, 193–208 [crossref], [Google Scholar], [Publisher]
- Durcin, A. Fleury, E. Taillebois, G. Hilairet, Z. Krupova, C. Henry, S. Truchet, M. Trötzmüller, H. Köfeler, G. Mabilleau, O. Hue, R. Andriantsitohaina, P. Martin, S. Le Lay, J. Extracell. Vesicles, 2017, 6, 1305677 [crossref], [Google Scholar], [Publisher]
- Rontogianni, E. Synadaki, B. Li, M.C. Liefaard, E.H. Lips, J. Wesseling, W. Wu, M. Altelaar, Commun. Biol., 2019, 2, 325 [crossref], [Google Scholar], [Publisher]
- Xu, A. Rai, M. Chen, W. Suwakulsiri, D.W. Greening, R.J. Simpson, Nat. Rev. Clin. Oncol., 2018, 15, 617–638 [crossref], [Google Scholar], [Publisher]
- Lu, S. Ling, A.M. Hegde, L.A. Byers, K. Coombes, G.B. Mills, R. Akbani, Semin. Oncol., 2016, 43, 476–483 [crossref], [Google Scholar], [Publisher]
- T. Tang, Y.Y. Huang, L. Zheng, S.H. Qin, X.P. Xu, T.X. An, Y. Xu, Y.S. Wu, X.M. Hu, B.H. Ping, Q. Wang, Int. J. Mol. Med., 2017, 40, 834–844 [crossref], [Google Scholar], [Publisher]
- S. Hong, S. Funk, L. Muller, M. Boyiadzis, T.L. Whiteside, J. Extracell. Vesicles, 2016, 5, 29289 [crossref], [Google Scholar], [Publisher]
- Stranska, L. Gysbrechts, J. Wouters, P. Vermeersch, K. Bloch, D. Dierickx, G. Andrei, R. Snoeck, J. Transl. Med., 2018, 16, 1 [crossref], [Google Scholar], [Publisher]
- Wang, K.W. Anderson, I.V. Turko, Anal. Chem., 2017, 89, 11070–11075 [crossref], [Google Scholar], [Publisher]
- Galindo-Hernandez, S. Villegas-Comonfort, F. Candanedo, M.C. González-Vázquez, S. Chavez-Ocaña, X. Jimenez-Villanueva, M. Sierra-Martinez, E.P. Salazar, Arch. Med. Res., 2013, 44, 208–214 [crossref], [Google Scholar], [Publisher]
- G. Moon, J.E. Lee, Y.E. Cho, S.J. Lee, Y.S. Chae, J.H. Jung, I.S. Kim, H.Y. Park, M.C. Baek, Oncotarget, 2016, 7, 40189–40199 [crossref], [Google Scholar], [Publisher]
- D. Ganggayah, N.A. Taib, Y.C. Har, P. Lio, S.K. Dhillon, BMC Med. Inform. Decis. Mak., 2019, 19, 48 [crossref], [Google Scholar], [Publisher]
- Rothammer, E.K. Sage, C. Werner, S.E. Combs, G. Multhoff, Radiat. Oncol., 2019, 14, 78 [crossref], [Google Scholar], [Publisher]
- Liu, L.N. Gu, B.E. Shan, C.Z. Geng, M.X. Sang, Oncol. Lett., 2016, 12, 4869–4876 [crossref], [Google Scholar], [Publisher]
- Kim, S. Lee, D. Seo, D. Kim, K. Kim, E. Kim, J. Kang, K.M. Seong, H. Youn, B. Youn, Cells, 2019, 8, 1105 [crossref], [Google Scholar], [Publisher]
- Raziani Y., Othman BS., 2021, 10: 5 [Crossref], [Google Scholar], [Publisher]
- S Ghorbanizadeh S., Raziani Y., Amraei M., Heydarian M., 2021, 12:54 [Crossref], [Google Scholar], [Publisher]
- Y Raziani Y., Othman BS., Raziani S., 69, 102739 [Crossref], [Google Scholar], [Publisher]
- Raziani Y., Raziani S., 2021, 3:83 [Crossref], [Google Scholar], [Publisher]
)